Overview

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

Status:
Withdrawn
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19 infection in hospitalized subjects with ARD/ARDS.
Phase:
Phase 2
Details
Lead Sponsor:
Sorrento Therapeutics, Inc.